Recent Advances in the Management of
Epilepsy: Expert Treatment Strategies for Improving Clinical and
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session from the 2020 Spring Managed Care Forum. If you
participated in the live session, you are not eligible for
continuing education credits from this archive
This activity is valid from June 1, 2020 to
June 1, 2021
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation, and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post-test to receive continuing education credits.
If you do not pass the post-test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post-test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from Eisai
Epilepsy is a chronic neurological disorder where the nerve cell
activity in the brain becomes disrupted, causing seizures or periods
of unusual behavior. Epilepsy affects about 3 million people in the
United States and accounts for about $15 billion in medical costs.
For about 70 percent of those diagnosed with epilepsy, seizures can
be controlled with medications and different surgical techniques.
Some drugs are more effective for specific types of seizures.
Patients who experience seizures, particularly those that are not
easily controlled, need to seek out neurological guidance. The goal
for neurologists is to achieve a seizure-free status for their
patients without adverse effects. With that said there are still
around 60% of patients that require treatment with anticonvulsants.
The diagnosis of epileptic seizures is made by analyzing the
patient's clinical history as well as performing neurophysiological
and neuroimaging tests. Treatment of epilepsy involves reducing the
number of seizures by administering various antiepileptic drugs (AEDs).
This approach requires long-term adherence from patients.
Unfortunately, more than one-third of people who experience seizures
continue to have issues despite the medication given. Many patients
do not have all the treatments available to them because their
seizures are not adequately controlled, or because they experience
severe adverse effects. The development of new AEDs continues to
increase and drug therapies can now be individualized to the
patient’s symptoms and needs. It is also important to understand the
mechanisms of action and the pharmacokinetics of antiepileptic drugs
so that these agents can be used effectively in clinical practice,
especially in the combined therapeutic strategies. Despite many of
the available AED options, there is still a need for medications
with novel mechanisms of action that are effective and well
tolerated. Uncontrolled seizures and their associated comorbidities,
such as depression, can have detrimental effects on the patient’s
quality of life.
Upon completion of this
activity, participants will be able to:
Differentiate current and emerging
antiepileptic drugs (AEDs) based on the latest evidence for
their efficacy, safety, and adherence potential
Develop optimal diagnostic goals for
patients with epilepsy, including the impact of genetic
Assess the latest guideline
recommendations and clinical evidence to develop optimal
personalized treatment strategies for patients with epilepsy
Identify and overcome challenges of
epilepsy management with the goal of reducing seizure burden,
improving adherence and reducing adverse events
Analyze the managed care
considerations of current and emerging therapies by exploring
where these agents fit in the epilepsy management paradigm
therapies in relapsed/refractory multiple myeloma management in
order to improve patient adherence
||Joseph I. Sirven, MD
Professor, Chair Emeritus
Division of Epilepsy
Department of Neurology
Mayo Clinic in Florida
serves as a consultant for Neurelis, GW Pharma, UCB
Pharma, Neuropace Inc., SK Pharma, Otsuka, Department of
Defense, and the Federal Aviation Authority. He has
received grants/research support from UCB, Biogen, and
Eisai. His presentation has been peer reviewed for any
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Will Williams has no relevant financial relationships to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This presentation is supported by
an educational grant from Eisai
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue